A EFFACER

Browse trials
List  

treatment    comparator  death (overall survival) (0)progression or death (progression free survival PFS) (1)Adverse events leading to treatment discontinuation (2)objective response (ORR) (3)Grade 3–5 drug-related AEs (4)Grade 3–5 drug-related AEs (5)serious drug-related adverse events (6)recurrence free survival (7)toxic death (8)vitiligo any grade (9)vitiligo grade 3-4 (10)distant metastasis free survival (11)aaa (12) Edit
Ipilimumabmelanoma, in adjuvant 1 - NOVARTIS vs placebo by 28% by 24% -- by 107% by 107% - by 24% --- by 24% -
Nivolumabmelanoma, in adjuvant 1 - NOVARTIS vs ipilimumab- by 35% by 77% - by 69% by 69% - by 35% -----
Pembrolizumabmelanoma, in adjuvant 1 - NOVARTIS vs placebo- by 43% -- by 335% by 335% - by 43% - by 196% NS--
Vemurafenibmelanoma, in adjuvant 1 - NOVARTIS vs placeboNS by 35% -----------
Trametinib + dabrafenib melanoma, in adjuvant 1 - NOVARTIS vs placebo by 43% by 53% ---------- by 49%
Trametinib + dabrafenib melanoma, in adjuvant 1 - NOVARTIS vs SOC-------------
Interferon alphamelanoma, in adjuvant 1 - NOVARTIS vs observationNS by 13% ---------NS-